xRead - Nasal Obstruction (September 2024) Full Articles

20426984, 0, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/alr.23262, Wiley Online Library on [02/01/2024]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License

206

KUANetal.

TABLE XXII.A.1 (Continued) Study

Year LOE Study design Study groups

Clinical endpoints Conclusion

Projetti et al. 1165 2015 4

1. MET protein was

1. To evaluate MET protein levels by IHC 2. To evaluate MET amplification and/or chromosome 7 polysomy by DISH 3. PFS 4. OS

72 cases of sinonasal ITAC treated with surgery ( n = 5); surgery followed by adjuvant RT ( n = 65); exclusive RT( n = 1); primary CRT( n = 1).

Retrospective case series study

overproduced in about two thirds of ITACs, suggesting a possible role for this tyrosine kinase receptor in ITAC oncogenesis. 2. Protein overproduction was not due to gene amplification, and the underlying mechanism remains to be determined 3. Anti-MET treatments would be of interest in ITACs Adjuvant IMRT is recommended in advanced-stage ITAC (pT3–pT4) and high-grade (G2–G3) early-stage (pT1–pT2) cases Mortality and systemic complications seem to be reduced with EEA, even when skull base removal is performed, in comparison with open CFR 1. The functional status of P53 can be helpful to identify the subgroup of chemoresponsive tumors 2. The response to induction chemotherapy represents a positive prognostic factor

Turri-Zanoni et al. 1150

2015 4

Retrospective

57 cases of sinonasal ITAC, early staged (T1-T2), surgically treated with EEA,

1. OS 2. DFS 3. Stratification of

case–control study

patients according to adjuvant RT

with at least 24 months of follow-up

Vergez et al. 1166

1. Hospitalization time 2. Complication rate 3. Margin status 4. Recurrence rate andRFS 5. Mortality 1. OS 2. DFS 3. Stratification of patients according to P53 functional status

136 cases of sinonasal ITAC surgically treated with EEA

2014 4

Retrospective

multicenter case–control study

Bossi et al. 102

2013 4

Retrospective case series

74 cases of sinonasal ITAC, divided into two groups: A( n = 30): patients treated with CFR followed by postoperative RT B( n = 44): patients

treated with primary chemotherapy

followed by CFR and RT (selected cases).

Cantu et al. 1152

1. ITAC has an indisputable

1. To explore the relationship

153 cases of sinonasal ITAC, surgically treated with CFR (96.7%) or with transfacial ethmoidectomy (3.3%)

2010 4

Retrospective

relationship with exposure to organic dusts, mainly wood and leather

case–control study

between ITAC and organic dusts

2. The CYP1A1 codon461 polymorphism is

2. OS 3. DFS 4. Incidence of the

overrepresented in ITAC and is often associated with the GSTM1 null genotype

polymorphisms of the enzymes CYP1A1 and GSTM1

Abbreviations: CFR, craniofacial resection; CSF, cerebrospinal fluid; CSS, cancer-specific survival; DFS, disease-free survival; DISH, dual color silver-enhanced in situ hybridization; DRFS, distant recurrence-free survival; EEA, endoscopic endonasal approach; ERTC, endoscopic resection with transnasal craniectomy; IHC, immunohistochemistry; IMRT, intensity-modulated radiotherapy; ITAC, intestinal-type adenocarcinoma; LOE, level of evidence based on the Oxford Cen tre for Evidence-Based Medicine Working Group; LRFS, local recurrence-free survival; OS, overall survival; pCR, pathologic complete response; PFL, cisplatin, fluorouracil, and leucovorin; PFS, progression-free survival; RFS, recurrence-free survival; RRFS, regional recurrence-free survival; RT, radiation therapy; TILs, tumor-infiltrating lymphocytes, TMIT, tumor microenvironment immune type.